Blood Cancers | Tumor

Oral Inqovi Safe and Effective Alternative MDS, CMML Treatment

January 29th 2024, 8:00pm

Article

Findings from the ASCERTAIN trial support the use of oral Inqovi for adults with intermediate- and high-risk myelodysplastic syndromes (MDS) such as chronic myelomonocytic leukemia (CMML).

Financial Burdens Harm Quality of Life After Stem Cell Transplants

January 16th 2024, 4:00pm

Article

Financial burdens from medical costs negatively affect quality of life in patients who have received stem cell transplants, recent research showed.

FDA Gives Cancer Drug Updates, Prostate Cancer Trial Enrolls Patients

January 15th 2024, 4:00pm

Podcast

Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

Novel Drug Shows 100% Disease Control Rate in WM

January 9th 2024, 4:00pm

Article

A small study of iopofosine I 131 in patients with pretreated Waldenstrom’s macroglobulinemia showed that the disease control rate was 100%.

AML Survivor Tells Patients Waiting for a Stem Cell Donor ‘Don’t Ever Give Up Hope’

October 6th 2023, 7:00pm

Article

For Maggie Cambora, who received a diagnosis of acute myeloid leukemia in 2020, the third potential donor match was the connection that saved her life, she told CURE®.

FDA Lifts Partial Hold on Trial Investigating Emavusertib in Lymphoma

August 19th 2022, 7:00pm

Article

The FDA has allowed the manufacturer of emavusertib to continue a phase 1/2 study investigating effects of the treatment in patients with lymphoma.

FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer

June 27th 2022, 9:00pm

Article

Treatment with the novel CAR-T cell therapy was associated with favorable efficacy and safety results in a group of patients with follicular lymphoma, including a few with Waldenstrom macroglobulinemia, according to findings from a study presented at a recent medical conference.

Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia

June 10th 2022, 9:00pm

Article

Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results

May 2nd 2022, 9:00pm

Article

The trial of CLR 131 (iopofosine) for relapsed/refractory Waldenstrom’s macroglobulinemia will continue, as the drug will be studied in an estimated 50 patients.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021, 8:00pm

Article

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.